Sökresultat

16 December 2025 15:15 to 16:00 | Seminar 14:45 - 15:15 Coffee 15:15 - 16:00 Seminar Professor Tarek Abdelzaher, Computer Science, University of Illinois at Urbana Champaign, USA Register at: https://survey.mailing.lu.se/Survey/62026 Title: The Bottlenecks in Advancing Foundation Models for Internet of Things (IoT) ApplicationsAbstract: Advances in self-supervised AI revolutionized modern machine

https://www.compile.lu.se/calendar/wasp-seminar-tarek-abdelzaher-bottlenecks-advancing-foundation-models-internet-things-iot - 2025-11-19

14 January 2026 12:00 to 13:00 | Seminar Topic: Pilot Testing a Unified AI Platform for Enhanced Learning (Phase II)When: 14 January 12.00 to 13.00Where: Online - link by registrationSpeaker: Burak Tunca, Director of AI Integration for education in Business Administration, LUSEM, Lund universitySpoken language: EnglishAbstractDuring the Autumn 2025 semester, I have been pilot testing a central, co

https://www.compile.lu.se/calendar/ai-lund-lunch-seminar-pilot-testing-unified-ai-platform-enhanced-learning-phase-ii - 2025-11-19

2 March 2026 09:30 to 15:30 | Workshop Fika-to-fika workshop by Lund University Profile Area Natural and Artificial Cognition. This one day (“fika-to-fika”) workshop brings together researchers from across the NAC Plane* who are working on  cognition, decision making, robots and AI-related topics.When: 2 March 2026 at 9.30 to 15.30Where:  TBDPrimary audience researchers (estimate: ???  attendants)

https://www.compile.lu.se/calendar/dolphins-decision-making-robots-and-ai - 2025-11-19

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl BorrebaeckChairman of the Boardcarl [dot] borrebaeck [at] immun [dot] lth [dot] se (carl[dot]borrebaeck[at]immun[d

https://www.createhealth.lth.se/about/centre-management-and-board - 2025-11-19

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment - 2025-11-19

 Please wait...

https://www.createhealth.lth.se/about/principle-investigators - 2025-11-19

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ

https://www.createhealth.lth.se/research-and-innovation/ongoing-collaborations-and-partners - 2025-11-19

CantargiaCantargia AB was founded in 2009/2010 by Thoas Fioretos and Marcus Järås (Lund University), Kjell Sjöström (Innovagen), and by LU Bioscience. The company specializes in antibody-based cancer therapy. After initially focusing on treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC), new antibodies designed for the treatment of autoimmune and inflammatory diseases hav

https://www.createhealth.lth.se/research-and-innovation/spin-outs - 2025-11-19

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology

https://www.createhealth.lth.se/canfaster - 2025-11-19

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/canfaster/publications - 2025-11-19

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1sNext generation immuno-oncological targets for cancer therapySubtype-dependent biomarkers for systemic therapy in bladder cancer

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects - 2025-11-19

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2025-11-19

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2025-11-19

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2025-11-19

Address Medicon Village - Building 406Sheelevägen 2 223 81 LundSweden Are you applying for a position? For general questions regarding the call, contact us at:canfaster-postdoc [at] immun [dot] lth [dot] se (canfaster-postdoc[at]immun[dot]lth[dot]se) DirectorSara Ek, Professorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se)+46-46-222-3824 Research coordinatorJana H

https://www.createhealth.lth.se/canfaster/contact - 2025-11-19

 Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden

https://www.createhealth.lth.se/contact - 2025-11-19

Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solutions, which can be implemented into the clinic with much shorter lead times. CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and pr

https://www.createhealth.lth.se/about - 2025-11-19

Promising results for Lead Biologics’ first-in-class checkpoint inhibitor published in Nature Cancer  Lead Biologics takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced experimental models.– This confirms the great interest in

https://www.createhealth.lth.se/news-0 - 2025-11-19

Focus AreasPsychological Resilience in Cancer, Bioinformatics and AIOngoing Collaborations and partnersCantargia, IMMUNOVIA, Paindrainer, Akuru PharmaSpin OutsWorking together is an integral part of CREATE Health’s DNA 

https://www.createhealth.lth.se/research-and-innovation - 2025-11-19

CREATE Health has been a leader in developing novel therapeutic and diagnostic innovations, which have been further developed in a commercial setting in a start-up company. Immuno-OncologyImmuno-oncology has provided a number of very exciting clinical improvements, by focussing on how the immune system regulates tumor eradication. This has been achieved by the discovery and functional implementati

https://www.createhealth.lth.se/research-and-innovation/focus-areas - 2025-11-19